Editing Smallpox vaccine (section)

== Safety ==
Vaccinia is infectious, which improves its effectiveness, but causes serious complications for people with impaired [[immune system]]s (for example [[chemotherapy]] and [[AIDS]] patients) or history of eczema, and pregnant women. It is also not recommended for anyone who lives with someone who belongs to any of the aforementioned groups.<ref>{{cite journal | vauthors = Rotz LD, Dotson DA, Damon IK, Becher JA | title = Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 | journal = MMWR. Recommendations and Reports | volume = 50 | issue = RR-10 | pages = 1–25; quiz CE1–7 | date = June 2001 | pmid = 15580803 | url = <!-- Official URL --> https://www.cdc.gov/mmwr/PDF/rr/rr5010.pdf | access-date = 13 June 2022 | archive-date = 13 October 2021 | archive-url = https://web.archive.org/web/20211013105825/https://www.cdc.gov/mmwr/pdf/rr/rr5010.pdf | url-status = live }}</ref> According to the US [[Centers for Disease Control and Prevention]] (CDC), "within 3 days of being exposed to the virus, the vaccine might protect you from getting the disease. If you still get the disease, you might get much less sick than an unvaccinated person would. Within 4 to 7 days of being exposed to the virus, the vaccine likely gives you some protection from the disease. If you still get the disease, you might not get as sick as an unvaccinated person would."<ref>{{cite web | title=Prevention and Treatment | website=U.S. [[Centers for Disease Control and Prevention]] (CDC) | date=18 October 2021 | url=https://www.cdc.gov/smallpox/prevention-treatment/index.html | access-date=11 August 2022 | archive-date=15 December 2017 | archive-url=https://web.archive.org/web/20171215110657/https://www.cdc.gov/smallpox/prevention-treatment/index.html | url-status=live }} {{PD-notice}}</ref>

In May 2007, the [[Vaccines and Related Biological Products Advisory Committee]] (VRBPAC) of the US [[Food and Drug Administration]] (FDA) voted unanimously that a new live virus vaccine produced by [[Acambis]], [[ACAM2000]], is both safe and effective for use in persons at high risk of exposure to smallpox virus. However, due to the high rate of serious adverse effects, the vaccine will only be made available to the CDC for the [[Strategic National Stockpile]].<ref>{{cite web | publisher = U.S. [[Food and Drug Administration]] (FDA) | title = Vaccines and Related Biological Products Advisory Committee Meeting | date = 17 May 2007 | access-date = 2 May 2013 | url = https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B2-00-index.htm | archive-date = 20 October 2017 | archive-url = https://web.archive.org/web/20171020103830/https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B2-00-index.htm | url-status = dead }} {{PD-notice}}</ref> ACAM2000 was approved for medical use in the United States in August 2007.<ref name="FDA ACAM2000" />